Spots Global Cancer Trial Database for Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years
Official Title: Phase I/II Clinical Study of SU11248 (Sutent) Combined With Standard Chemotherapy With Cytosine Arabinoside and Daunorubicin in Patients With FLT3 Mutated AML Over 60 Years of Age
Study ID: NCT00783653
Conditions
Interventions
Study Description
Brief Summary: In this study safety and tolerability of two dose levels of SU 11248 (sutent) with standard chemotherapy in patients with FLT3 mutated AML over 60 years will be evaluated.
Detailed Description:
Eligibility
Minimum Age: 60 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Prof. Dr. med. Walter Fiedler, Hamburg, , Germany
PD Dr. med. Jürgen Krauter, Hannover, , Germany
Dr. Katharina Götze, München, , Germany
Prof. Dr. Helmut R. Salih, Tübingen, , Germany
Dr. Richard Schlenk, Ulm, , Germany
Contact Details
Name: Walter Fiedler
Affiliation: Universitätsklinikum Hamburg-Eppendorf
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
